GSK tries to lease vacant office space after layoffs; CVS agrees to buy Target's pharmacy biz for $1.9B;

@FiercePharma: G7 vows to combat antibiotics resistance, but animal health groups urge caution. More from FierceAnimalHealth | Follow @FiercePharma

@CarlyHFierce: ICYMI: Consumer group demands FDA correct 'compounded mistake' on Vanda's Hetlioz label. Report | Follow @CarlyHFierce

> After shedding a fifth of its workforce in Research Triangle Park, NC, GlaxoSmithKline ($GSK) is trying to lease up to 500,000 square feet of its vacant office space for temporary use by state government employees. More

> Startup Intarcia Therapeutics is aiming to disrupt the diabetes care market with a matchstick-size implant. More

> CVS ($CVS) has agreed to buy Target's ($TGT) pharmacy and clinic business for $1.9 billion. Report

> The federal magistrate recommendation that Kirkland & Ellis--lead takeover counsel for Teva ($TEVA) in its quest to buy Mylan ($MYL)--be thrown off the deal could have major law firms quickly redoing their procedures to avoid risking it happening to them. More

> Researchers from Boston Children's Hospital and Merck ($MRK) are looking into the relationship between social media use and sleep issues, and early findings suggest that patients with sleep disorders may be a greater risk of psychosocial issues. More

Medical Device News

@FierceMedDev: ICYMI Friday: Philips cautions on cardio mortality after ResMed sleep apnea data, intros cardiac imaging tool. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI Friday: Indian feds stake out plan to become a global hub of device manufacturing and innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: India's PM is facing pushback from MSF over access to generic drugs. More from Reuters| Follow @EmilyWFierce

> FDA approves St. Jude's neurostimulator for Parkinson's, setting up rivalry with Medtronic. Report

> Milestone Pharma raises $17M Series B for Phase II of at-home, drug-device cardiac arrhythmia combo. Story

> Study: Researchers find dual-hormone artificial pancreas best for treating nocturnal hypoglycemia. Article

Biotech News

@FierceBiotech: Briggs Morrison trades lead role in AstraZeneca R&D for the helm of tiny Syndax. News | Follow @FierceBiotech

@JohnCFierce: ICYMI: Bluebird bio builds its case for gene therapy as first sickle cell patient responds. Article | Follow @JohnCFierce

@DamianFierce: Listen to two arguably well-informed people talk about the week in biopharma. FierceBiotech Radio | Follow @DamianFierce

> AstraZeneca spells out key failures for gout drug in PhIII. More

> Israel's RedHill soars as its antibiotic comes through in Phase III. Story

> Avalon, GlaxoSmithKline launch 3 new biotechs with $30M commitment. Article

Animal Health News

> AB Science struggles to break out as canine cancer drug flounders. Report

> Rapamycin raises $2.5M to advance lead drug for treating cancer in pets. Item

> G7 vows to combat antibiotics resistance, but animal health groups urge caution. More

> Scientists scrambling to determine if virulent avian flu is airborne. Story

> Lilly quashes rumors of Elanco spinoff as stock soars. Article

Biotech IT News

> EHR-enabled data dive links stomach blockbusters to heart attacks. More

> Allergan slashes laptop use in full-throttle mobile push. Report

> Takeda taps Sanford for robotics, 3-D modeling skills in heart failure pact. Story

> The search for exceptional responders in tumor sequencing databases. Item

> J&J teams with Emulate to use organ-on-a-chip technology in R&D programs. Article

Pharma Marketing News

> PatientsLikeMe, FDA partner up to track online drug safety clues. Item

> CoheroHealth's 'smart,' mobile spirometer begins pilots with pharma, payers. News

> Experts urge FDA to step in to quash 'Low-T' awareness efforts. More

> Merck ramps up Belsomra marketing, hoping to wake up a sleepy insomnia market. Story

> Mannkind investors skittish after CEO, CFO update on Afrezza launch. Article

And Finally... A new app from a division of Johnson & Johnson ($JNJ) tells you the exact street where the flu and allergies are lurking in your neighborhood. More

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.